Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia

Inclusion Criteria: * Subject meets any of the following criteria and with sUA ≤10.0 mg/dL: 1. sUA level of \>7.0 mg/dL at 7 days prior to baseline with gout; 2. sUA level of ≥8.0 mg/dL at 7 days prior to baseline without gout but with complications (hypertension, ischemic heart disease, diabetes, metabolic syndrome); 3. sUA level of ≥9.0 mg/dL at 7 days prior to baseline without gout and complications. Exclusion Criteria: * Subject with an acute gout flare that has not resolved at least 14 days prior to the baseline visit. * Subject has a history or suspicion of kidney stones. * Subject has an estimated creatinine clearance \<60 mL/min calculated by the Cockcroft Gault formula * Subject is receiving strong or moderate CYP3A inhibitors